Key statistics
On Tuesday, Supernus Pharmaceuticals Inc (S49:MUN) closed at 29.00, -9.94% below its 52-week high of 32.20, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 29.00 |
---|---|
High | 29.00 |
Low | 29.00 |
Bid | 29.40 |
Offer | 29.80 |
Previous close | 29.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 55.11m |
Free float | 52.33m |
P/E (TTM) | 362.96 |
Market cap | 1.77bn USD |
EPS (TTM) | 0.0883 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 07:30 BST.
More ▼
Announcements
- Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Announces Second Quarter 2024 Financial Results
- Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
- Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
- Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
- Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
More ▼